Drug-induced Hepatic Sinusoidal Obstruction Syndrome: Current Advances and Future Perspectives

Overview

Journal Arch Toxicol

Specialty Toxicology

Date 2024 Dec 24

PMID 39718593

Authors

Zaoqin Yu

Wei Li

Cheng Tian

Yan Cao

Chengliang Zhang

Affiliations

Soon will be listed here.

Abstract

Hepatic sinusoidal obstruction syndrome (HSOS) has gained recognition as a rare form of drug-induced liver injury (DILI) in recent years. Although extensively studied in the context of hematopoietic stem cell transplantation (HSCT), the applicability of this knowledge to drug-induced HSOS remains limited due to distinct etiological factors. The primary causes of drug-induced HSOS include the ingestion of pyrrolizidine alkaloid (PA)-containing plants, as well as the use of chemotherapeutic agents and immunosuppressive drugs. The underlying pathogenesis is not yet fully understood. Noninvasive diagnostic imaging modalities such as ultrasonography, computed tomography, and magnetic resonance imaging play a valuable role in diagnosis. Further research is essential to develop standardized severity grading systems and optimize treatment strategies. This review summarizes the key etiologies, pathological mechanisms, clinical features, diagnostic approaches, severity assessment, and therapeutic options for drug-induced HSOS.

References

Arakawa Y, Shimada M, Utsunomiya T, Imura S, Morine Y, Ikemoto T . Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy. Anticancer Res. 2014; 34(4):1953-8. View

Arndt C, Hawkins D, ANDERSON J, Breitfeld P, Womer R, Meyer W . Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol. 2004; 22(10):1894-901. DOI: 10.1200/JCO.2004.08.075. View

Barcelos S, DallOglio V, de Araujo A, Cerski C, Alvares-da-Silva M . Sinusoidal obstruction syndrome secondary the intake of Senecio brasiliensis: A case report. Ann Hepatol. 2019; 20:100138. DOI: 10.1016/j.aohep.2019.08.009. View

Cayet S, Pasco J, Dujardin F, Besson M, Orain I, De Muret A . Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation. Eur J Radiol. 2017; 94:180-190. DOI: 10.1016/j.ejrad.2017.06.025. View

Cecen E, Uysal K, Ozguven A, Gunes D, Irken G, Olgun N . Veno-occlusive disease in a child with rhabdomyosarcoma after conventional chemotherapy: report of a case and review of the literature. Pediatr Hematol Oncol. 2007; 24(8):615-21. DOI: 10.1080/08880010701640390. View

Cesaro S, Spiller M, Sartori M, Alaggio R, Peruzzo M, Saggiorato G . Veno-occlusive disease in pediatric patients affected by Wilms tumor. Pediatr Blood Cancer. 2011; 57(2):258-61. DOI: 10.1002/pbc.22841. View

Charvet E, Lheure C, Isnard C, Franck N, Kramkimel N, Vallet-Pichard A . Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report. Ann Oncol. 2020; 31(5):661-662. DOI: 10.1016/j.annonc.2020.02.004. View

Choi A, Kang Y, Lim S, Kim D, Lim J, Lee J . Severe Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with Defibrotide. Cancer Res Treat. 2016; 48(4):1443-1447. PMC: 5080818. DOI: 10.4143/crt.2016.096. View

Chojkier M . Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol. 2003; 39(3):437-46. DOI: 10.1016/s0168-8278(03)00231-9. View

10.

Craft P, Pembrey R . Veno-occlusive disease of the liver following chemotherapy with mitomycin C and doxorubicin. Aust N Z J Med. 1987; 17(4):449-51. DOI: 10.1111/j.1445-5994.1987.tb00089.x. View

11.

DAntiga L, Baker A, Pritchard J, Pryor D, Mieli-Vergani G . Veno-occlusive disease with multi-organ involvement following actinomycin-D. Eur J Cancer. 2001; 37(9):1141-8. DOI: 10.1016/s0959-8049(01)00097-1. View

12.

de Ledinghen V, Villate A, Robin M, Decraecker M, Valla D, Hillaire S . Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2020; 44(4):480-485. DOI: 10.1016/j.clinre.2020.03.019. View

13.

DeAngelo D, Stock W, Stein A, Shustov A, Liedtke M, Schiffer C . Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv. 2018; 1(15):1167-1180. PMC: 5728308. DOI: 10.1182/bloodadvances.2016001925. View

14.

DeLeve L . Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology. 1996; 24(4):830-7. DOI: 10.1002/hep.510240414. View

15.

Dignan F, Wynn R, Hadzic N, Karani J, Quaglia A, Pagliuca A . BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013; 163(4):444-57. DOI: 10.1111/bjh.12558. View

16.

Druet A, Mosnier J, Corbineau E, Matysiak-Budnik T, Touchefeu Y, Viala C . Defibrotide for Sinusoidal Obstruction Syndrome and Nodular Regenerative Hyperplasia After Oxaliplatin-Based Hepatic Intra-Arterial Chemotherapy: A Case Report. Clin Colorectal Cancer. 2021; 21(2):e98-e101. DOI: 10.1016/j.clcc.2021.10.003. View

17.

Duncan C, Martin A, Perez W, Steinert P, Zhang M, Chirnomas D . Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation. Pediatr Blood Cancer. 2021; 68(8):e29067. PMC: 8324076. DOI: 10.1002/pbc.29067. View

18.

Dusemund B, Nowak N, Sommerfeld C, Lindtner O, Schafer B, Lampen A . Risk assessment of pyrrolizidine alkaloids in food of plant and animal origin. Food Chem Toxicol. 2018; 115:63-72. DOI: 10.1016/j.fct.2018.03.005. View

19.

Esbah O, Tekgunduz E, Demiriz I, Bozdag S, Kaya A, Tetik A . Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE. Turk J Haematol. 2015; 33(3):209-15. PMC: 5111466. DOI: 10.4274/tjh.2014.0214. View

20.

Fagiuoli S, Bruno R, Debernardi Venon W, Schepis F, Vizzutti F, Toniutto P . Consensus conference on TIPS management: Techniques, indications, contraindications. Dig Liver Dis. 2016; 49(2):121-137. DOI: 10.1016/j.dld.2016.10.011. View